参考文献/References:
[1] Boskovski MT,Gleason TG. Current therapeutic options in aortic stenosis[J]. Circ Res,2021,128(9):1398-1417.
[2] Coffey S,Cox B,Williams MJ. The prevalence,incidence,progression,and risks of aortic valve sclerosis:a systematic review and meta-analysis[J]. J Am Coll Cardiol,2014,63(25 Pt A):2852-2861.
[3] Joseph J,Naqvi SY,Giri J,et al. Aortic stenosis:pathophysiology,diagnosis,and therapy[J]. Am J Med,2017,130(3):253-263.
[4] Vahanian A,Beyersdorf F,Praz F,et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease[J]. Eur Heart J,2022,43(7):561-632.
[5] Merlini G,Bellotti V. Molecular mechanisms of amyloidosis[J]. N Engl J Med,2003,349(6):583-596.
[6] Buxbaum JN,Dispenzieri A,Eisenberg DS,et al. Amyloid nomenclature 2022:Update,novel proteins,and recommendations by the international society of amyloidosis (ISA) nomenclature committee[J]. Amyloid,2022,29(4):213-219.
[7] Sipe JD,Benson MD,Buxbaum JN,et al. Amyloid fibril protein nomenclature:2010 recommendations from the nomenclature committee of the international society of amyloidosis[J]. Amyloid,2010,17(3-4):101-104.
[8] Castano A,Narotsky DL,Hamid N,et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement[J]. Eur Heart J,2017,38(38):2879-2887.
[9] Galat A,Guellich A,Bodez D,et al. Aortic stenosis and transthyretin cardiac amyloidosis:the chicken or the egg?[J]. Eur Heart J,2016,37(47):3525-3531.
[10] Ternacle J,Krapf L,Mohty D,et al. Aortic stenosis and cardiac amyloidosis:JACC review topic of the week[J]. J Am Coll Cardiol,2019,74(21):2638-2651.
[11] Scully PR,Patel KP,Treibel TA,et al. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation[J]. Eur Heart J,2020,41(29):2759-2767.
[12] Treibel TA,Fontana M,Gilbertson JA,et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis:prevalence and prognosis in patients undergoing surgical aortic valve replacement[J]. Circ Cardiovasc Imaging,2016,9(8):e005066.
[13] Nitsche C,Scully PR,Patel KP,et al. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis[J]. J Am Coll Cardiol,2021,77(2):128-139.
[14] Kristen AV,Schnabel PA,Winter B,et al. High prevalence of amyloid in 150 surgically removed heart valves—a comparison of histological and clinical data reveals a correlation to atheroinflammatory conditions[J]. Cardiovasc Pathol,2010,19(4):228-235.
[15] Henderson BC,Tyagi N,Ovechkin A,et al. Oxidative remodeling in pressure overload induced chronic heart failure[J]. Eur J Heart Fail,2007,9(5):450-457.
[16] Bonelli A,Paris S,Nardi M,et al. Aortic valve stenosis and cardiac amyloidosis:a misleading association[J]. J Clin Med,2021,10(18):4234.
[17] Cavalcante JL,Rijal S,Abdelkarim I,et al. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis[J]. J Cardiovasc Magn Reson,2017,19(1):98.
[18] Kittleson MM,Maurer MS,Ambardekar AV,et al. Cardiac amyloidosis:evolving diagnosis and management:A scientific statement from the American Heart Association[J]. Circulation,2020,142(1):e7-e22.
[19] Merlini G,Dispenzieri A,Sanchorawala V,et al. Systemic immunoglobulin light chain amyloidosis[J]. Nat Rev Dis Primers,2018,4(1):38.
[20] 中华医学会心血管病学会心力衰竭学组,中华心血管病杂志编辑委员会. 转甲状腺素蛋白心脏淀粉样变诊断与治疗专家共识[J]. 中华心血管病杂志,2021,49(4):324-332.
[21] Martinez-Naharro A,Kotecha T,Norrington K,et al. Native T1 and extracellular volume in transthyretin amyloidosis[J]. JACC Cardiovasc Imaging,2019,12(5):810-819.
[22] Writing C,Kittleson MM,Ruberg FL,et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis:a report of the American College of Cardiology solution set oversight committee[J]. J Am Coll Cardiol,2023,81(11):1076-1126.
[23] Oda S,Emoto T,Nakaura T,et al. Myocardial late iodine enhancement and extracellular volume quantification with dual-layer spectral detector dual-energy cardiac CT[J]. Radiol Cardiothorac Imaging,2019,1(1):e180003.
[24] Bokhari S,Casta?o A,Pozniakoff T,et al. 99mTC-pyrophosphate scintigraphy for differentiating lightchain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses[J]. Cir Cardiovasc Imaging,2013,6(2):195-201.
[25] Hanna M,Ruberg FL,Maurer MS,et al. Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis:JACC review topic of the week[J]. J Am Coll Cardiol,2020,75(22):2851-2862.
[26] Witteles RM,Liedtke M. Avoiding catastrophe:understanding free light chain testing in the evaluation of ATTR amyloidosis[J]. Circ Heart Fail,2021,14(4):e008225.
[27] Vrana JA,Gamez JD,Madden BJ,et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens[J]. Blood,2009,114(24):4957-4959.
[28] Vahanian A,Beyersdorf F,Praz F,et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease[J]. Eur Heart J,2022,43(7):561-632.
[29] Pibarot P,Lancellotti P,Narula J. Concomitant cardiac amyloidosis in severe aortic stenosis:the trojan horse?[J]. J Am Coll Cardiol,2021,77(2):140-143.
[30] Jaiswal V,Agrawal V,Khulbe Y,et al. Cardiac amyloidosis and aortic stenosis:a state-of-the-art review[J]. Eur Heart J Open,2023,3(6):oead106.
[31] Heidenreich PA,Bozkurt B,Aguilar D,et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure:a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. J Am Coll Cardiol,2022,79(17):e263-e421.
[32] Griffin JM,Rosenthal JL,Grodin JL,et al. ATTR Amyloidosis: Current and Emerging Management Strategies: JACC: CardioOncology State-of-the-Art Review[J]. JACC:CardioOncology,2021,3(4):488-505.
[33] Maurer MS,Schwartz JH,Gundapaneni B,et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy[J]. N Engl J Med,2018,379(11):1007-1016.
[34] Ackermann EJ,Guo S,Benson MD,et al. Suppressing transthyretin production in mice,monkeys and humans using 2nd-generation antisense oligonucleotides[J]. Amyloid,2016,23(3):148-157.
[35] Benson MD,Waddington-Cruz M,Berk JL,et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis[J]. N Engl J Med,2018,379(1):22-31.
[36] 中国系统性轻链型淀粉样变性协助组,国家肾脏疾病临床医学研究中心,国家血液系统疾病临床医学研究中心. 系统性轻链型淀粉样变性诊断和治疗指南（2021年修订）[J]. 中华医学杂志,2021,101(22):1646-1656.
[37] Gertz MA. Immunoglobulin light chain amyloidosis:2018 update on diagnosis,prognosis,and treatment[J]. Am J Hematol,2018,93(9):1169-1180.
相似文献/References:
[1]于海波,综述,梁延春,等.经导管主动脉瓣膜置换术后房室传导阻滞的预警[J].心血管病学进展,2016,(4):419.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.024]
YU Haibo,LIANG Yanchun.Predicting Factors of Atrioventricular Block after Transcatheter
Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2016,(8):419.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.024]
[2]谢晓川,饶莉.经导管主动脉瓣植入术临床研究进展[J].心血管病学进展,2015,(6):700.[doi:10.3969/j.issn.1004-3934.2015.06.011]
XIE Xiaochuan,RAO Li.Clinical Research Progress in Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2015,(8):700.[doi:10.3969/j.issn.1004-3934.2015.06.011]
[3]于子凯 许海燕 刘庆荣 吴永健.合并常见疾病对经导管主动脉瓣置换术患者预后的影响[J].心血管病学进展,2019,(5):697.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.009]
YU Zikai,XU Haiyan,LIU Qingrong,et al.Influence of ommon Accompanied Diseases on Prognosis of Patients after Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2019,(8):697.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.009]
[4]邵美华 周玉强 王萌萌 王宝珠 马翔.经导管主动脉瓣置换术治疗二叶式主动脉瓣狭窄研究进展[J].心血管病学进展,2020,(11):1184.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[5]夏平.“8+2”心电图临床价值的研究进展夏平[J].心血管病学进展,2021,(9):800.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2021.09.009]
XIA Ping.Clinical Value of 8 Plus 2 ECG[J].Advances in Cardiovascular Diseases,2021,(8):800.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2021.09.009]
[6]李宗泽 何贵均 郑晓菲 蒋晖 刘汉雄.经导管主动脉瓣置换术后合并心房颤动的抗栓策略[J].心血管病学进展,2021,(10):892.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.007]
LI ZongzeHE GuijunZHENG XiaofeiJIANG HuiLIU Hanxiong.Optimal Antithrombotic Strategies after Transcatheter Aortic Valve Replacement in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(8):892.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.007]
[7]熊群 董剑廷 杨昂.转甲状腺素蛋白心脏淀粉样变磁共振影像学进展[J].心血管病学进展,2022,(4):305.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.005]
XIONG Qun,DONG Jianting,YANG Ang.Magnetic Resonance Imaging of Transthyretin Cardiac Amyloidosis[J].Advances in Cardiovascular Diseases,2022,(8):305.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.005]
[8]王卫卫 于子凯 吴永健 许海燕 刘庆荣.序贯综合心脏康复模式在经导管主动脉瓣置换术患者中应用现状[J].心血管病学进展,2022,(8):673.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.001]
WANG Weiwei,YU Zikai,WU YongjianXU HaiyanLIU Qingrong.The Status of Sequential Comprehensive Cardiac Rehabilitation in Patients?ndergoing Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(8):673.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.001]
[9]张航 安景辉 石凤梧.极简式经导管主动脉瓣置换术的研究现状[J].心血管病学进展,2022,(9):812.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.011]
ZHANG Hang,AN Jinghui,SHI Fengwu.Minimalist Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(8):812.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.011]
[10]达尼亚尔·迪力木拉提 施林 严飞.二叶式主动脉瓣发病机制及其临床诊治的研究进展[J].心血管病学进展,2023,(5):412.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.007]
Daniyar·Dilmurat,SHI Lin,YAN Fei.The PathogenesisClinical Diagnosis and Treatment of Bicuspid Aortic Valve[J].Advances in Cardiovascular Diseases,2023,(8):412.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.007]